A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune
hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks.